Quick Facts: Lomanor

• Primary Use: Management of high blood pressure (hypertension).
• Additional Use: Symptomatic relief for certain types of chest pain (angina).
• Therapeutic Role: Helps reduce the risk of certain cardiovascular events in patients with coronary artery disease.

---

What Lomanor Treats: Main Uses and Benefits

Lomanor is a prescription medication utilized in the management of high blood pressure, a condition often referred to as hypertension. By helping to maintain blood pressure within a desirable range, use of Lomanor may contribute to a reduced risk of major cardiovascular events. It is a suitable component of a comprehensive cardiovascular health plan.

In addition to its role in regulating blood pressure, this medication provides symptomatic relief for certain forms of chest discomfort known as angina. This includes both chronic stable angina and vasospastic angina (Prinzmetal’s or variant angina). The therapeutic effect of Lomanor may be observed in the treatment of coronary artery disease (CAD). In adult patients with confirmed CAD, it is indicated to help reduce the risk of hospitalization due to angina and to help reduce the need for coronary revascularization procedures. Lomanor can be used as a standalone treatment or in combination with other therapeutic agents for its approved indications. Discussion of a patient's individual treatment goals and health profile should occur with a qualified healthcare professional.

Lomanor (Amlodipine) eligibility is strictly defined by regulatory bodies and is organized into groups for whom use is approved, prohibited, or requires conditional caution.

Absolute Contraindication: Lomanor is contraindicated in patients with a known hypersensitivity (allergic reaction) to amlodipine, any dihydropyridine derivative, or any component of the formulation.

---

Age-Related Eligibility

Population	Eligibility Status (Official Labeling)
Adults (18+ years)	Approved for all labeled uses (hypertension and coronary artery disease).
Children (6–17 years)	Approved for hypertension only. Safety and effectiveness are not established for treating angina or in children under 6 years of age.
Geriatric Patients	Eligible, but caution is advised, and a lower initial dose may be necessary due to potential decreased clearance.

---

Conditional Use

Caution and close monitoring are required for patients with hepatic impairment (impaired liver function), as drug clearance is reduced in this population. No dosage adjustment is considered necessary for patients with renal impairment.

Use during pregnancy is permitted only if the potential benefit justifies the potential risk. Amlodipine is present in breast milk, and caution is advised during lactation.

Interactions with other medicines and products

This section outlines interactions with other medicinal products and substances as explicitly documented in official government regulatory documents.

Interaction Type	Interacting Substances/Category	Regulatory Statement
Pharmacokinetic Constraint	Simvastatin (Cholesterol-lowering drug)	Co-administration significantly increases Simvastatin exposure (AUC). Regulatory documents mandate that the Simvastatin dose be limited to a maximum of 20 mg daily when co-administered with Amlodipine.
Metabolic Enhancement Risk	Strong/Moderate CYP3A4 Inhibitors (e.g., Ketoconazole, Itraconazole, Clarithromycin)	Co-administration may give rise to a significant increase in Amlodipine systemic exposure as Amlodipine is primarily metabolized by CYP3A4. The clinical effect may be more pronounced in elderly patients.
Metabolic Reduction Risk	CYP3A4 Inducers (e.g., Rifampicin, St. John's Wort)	Co-administration may lead to reduced Amlodipine plasma concentrations, potentially decreasing its clinical effect.
Pharmacodynamic Enhancement	Other Anti-hypertensive Agents (e.g., Beta-blockers, Diuretics)	The blood pressure lowering effects of Amlodipine are additive to those of other medicinal products with anti-hypertensive properties.
Food/Substance Restriction	Grapefruit / Grapefruit Juice	Administration with grapefruit or its juice is not recommended as it may increase the bioavailability of Amlodipine.

Specific Considerations

Interactions involving Tacrolimus and Cyclosporine require careful monitoring of their respective blood levels and possible dose adjustment, due to a risk of increased exposure of these drugs. In patients with hepatic impairment, clearance of Amlodipine is decreased, leading to higher systemic exposure, which is a population-specific consideration for interaction risks.

Lomanor (Amlodipine) operates by highly selective and targeted inhibition of the physiological mechanism responsible for arterial constriction.

Vascular Smooth Muscle Ion Channel Blockade

This mechanism covers Lomanor's action as a specific antagonist (blocker) of the L-type voltage-gated calcium channels ( Ca v1.2). By binding to the channel, the drug physically limits the influx of extracellular calcium ions ( Ca^2+) into the arterial smooth muscle cells, which are necessary for the muscle contraction process.

Excitation-Contraction Pathway Modulation

The reduction in available Ca^2+ ions interferes with the excitation-contraction coupling pathway within the vascular muscle wall. This action disrupts the molecular sequence necessary for the muscle fibers to sustain contraction, leading to smooth muscle relaxation and the physical widening of peripheral blood vessels (vasodilation).

Systemic Vascular Resistance Reduction

The resulting widespread arterial vasodilation causes a fundamental reduction in the systemic vascular resistance (or afterload). This physiological adjustment is the core mechanical consequence of the drug's mechanism, which establishes the physiological basis for the drug’s action on circulatory dynamics.

Lomanor is administered by the oral route only, utilizing either the tablet form (2.5 mg, 5 mg, 10 mg) or an oral liquid. The medication is intended for chronic, long-term use and is taken once daily. To ensure consistent blood levels, it should be taken at the same time each day, and may be administered with or without food, as absorption is unaffected by meals.

Official Dosing Regimens

The standard initial oral dose for adults with approved indications is 5 mg once daily. A lower starting dose of 2.5 mg once daily is recommended for small or fragile patients, older adults, and individuals with hepatic impairment. The maintenance dose typically ranges from 5 mg to 10 mg once daily, and the maximum recommended daily dose is 10 mg for all adult indications.

Dosage Adjustment and Special Populations

Any change in dosage must be made slowly. In general, a period of 7 to 14 days should elapse between dose adjustments to fully assess the patient’s response to the current dose level. For pediatric patients aged 6 to 17 years being treated for hypertension, the effective oral dose is 2.5 mg to 5 mg once daily; doses higher than 5 mg have not been studied in this population. No dosage adjustment is typically required for patients with renal impairment, as changes in plasma concentrations are not significantly correlated with the degree of kidney function loss.

If a dose is missed, general patient instructions advise taking it as soon as possible, or skipping the missed dose and resuming the regular schedule if it is almost time for the next dose; a double dose must not be taken.

Research Evidence / Overview of Studies for Lomanor (Amlodipine)

The following summary describes the type of scientific research that has been conducted on Lomanor (Amlodipine), focusing on the structure of the evidence base according to regulatory and peer-reviewed sources. It does not provide medical advice or instructions.

---

Evidence for the Management of High Blood Pressure (Hypertension)

Research exploring the use of Lomanor for high blood pressure has relied on large-scale data, including long-term Randomized Controlled Trials (RCTs) and Cardiovascular Outcome Trials (CVOTs). Researchers designed these studies to examine how blood pressure measurements evolved over defined time intervals. The trials monitored outcomes related to both the physical measurements of blood pressure and major adverse cardiovascular events (e.g., stroke and myocardial infarction) over periods lasting several years.

The study populations included diverse groups, such as adults with different levels of high blood pressure and those with other health conditions. Specific trials were evaluated in groups of older adults and children aged 6 years and older.

Findings describe patterns observed in the studies related to blood pressure measurements. Long-term outcome trials reported patterns of cardiovascular events in the populations receiving Amlodipine-based regimens. In some studies, findings regarding specific non-fatal outcomes were observed to be varied when different treatment approaches were assessed. Data focusing on highly severe or treatment-resistant hypertension is less extensive than the evidence for more common types of hypertension.

---

Evidence for the Treatment of Angina and Coronary Artery Disease (CAD)

The research for Lomanor in treating chest discomfort (angina) and certain heart conditions was studied for both short-term symptom measures and longer-term procedural outcomes.

For Chronic Stable Angina, research used RCTs to explore outcomes related to functional measures, such as time recorded during exercise testing, and patient-reported frequency of acute symptom relief medication use. Studies reported specific changes measured during the study period for these functional endpoints. The evidence is limited for long-term reduction in cardiovascular mortality when this condition is studied in isolation.

For Coronary Artery Disease (CAD), large RCTs examined outcomes related to the need for certain heart procedures (revascularization) and hospitalization for unstable angina. The research described symptom patterns and procedural needs, but the evidence regarding event rates for heart attack or cardiovascular death in specific CAD cohorts may be less consistent than the reported reduction in procedures and hospitalizations.

---

Studies in Specific and Vulnerable Populations

Lomanor was studied for the treatment of severe Chronic Heart Failure (CHF), particularly in a subset of patients with non-ischemic causes. Initial trials reported mixed findings regarding mortality and hospitalization outcomes. A subsequent, larger trial designed to assess this specific hypothesis reported mixed findings. Therefore, the data for this indication are complex, and the evidence quality varies across studies for the overall CHF population.

---

What is Still Uncertain and Research Gaps

While large trials exist, there is limited information for long-term outcomes that extend significantly beyond the observation period of these studies. Therefore, the continuity of long-term data over a lifetime is not fully established. In some specific outcomes and subgroups, comparative evidence is lacking to fully characterize the observed patterns. Subgroup findings are uncertain and may not be generalizable to all patients. Findings describe group patterns, not personal outcomes, and research does not determine whether an individual will respond similarly.

Common questions about Lomanor (FAQ)

Q: What happens if Lomanor is stopped suddenly?

A: Regulatory documents advise that if you've been taking Lomanor regularly for several weeks, abruptly stopping the medicine may cause the condition being treated, such as high blood pressure or chest pain, to return or potentially worsen. It is important to consult a healthcare professional regarding any changes to your treatment regimen.

Q: How long does it typically take for a person to notice the effects of Lomanor?

A: Lomanor is designed to be a long-acting medication that provides gradual, sustained control over time. While the drug reaches peak concentration in the blood within 6 to 12 hours, official information indicates that a full blood pressure-lowering effect may take several days to a week of regular use to develop, based on clinical data.

Q: Are there any common foods or supplements that are known to interfere with Lomanor?

A: Official product information specifically cautions against consuming grapefruit or grapefruit juice, as this combination may increase the amount of Lomanor in the body. Additionally, the herbal supplement St. John's Wort is also listed as a potential inducer that may lower the amount of Lomanor in the blood, possibly reducing its effect.

Q: How quickly does Lomanor leave the body after the last dose?

A: Lomanor is a long-acting compound. Official data describes its elimination half-life—the time it takes for half the drug to leave the body—as 30 to 50 hours in adults. This long half-life means it takes an extended period for the substance to be completely cleared from the body after the last dose.

Q: Is Lomanor described as a controlled substance in any official documents?

A: Amlodipine, the active ingredient in Lomanor, is classified as a prescription-only drug. However, it is not listed as a controlled substance under the U.S. Controlled Substances Act (CSA) or similar international drug scheduling regulations.

Q: Are there documented cases of Lomanor causing allergic reactions, and what are the signs?

A: Official documents list hypersensitivity (allergic reaction) as a formal contraindication for Lomanor use. Severe signs that have been documented include swelling of the face, lips, tongue, or throat (angioedema), rash, hives, and difficulty breathing or swallowing.

Q: What is the general difference between Lomanor and older treatments for the same condition?

A: Lomanor is a type of calcium channel blocker (CCB) known as a dihydropyridine. Research indicates that this class offers a long duration of action, supporting once-daily dosing. Studies have also examined patterns in how the drug compares to older classes of blood pressure medicine, such as beta-blockers or diuretics, regarding cardiovascular outcomes.

Q: Does Lomanor interact with common over-the-counter pain relievers?

A: Official drug monographs do not typically list major documented interactions with common OTC pain relievers like acetaminophen or ibuprofen. However, some non-pain relief OTC ingredients, such as Oxymetazoline (found in certain nasal decongestants), may interfere with the drug’s blood pressure-lowering effects.

Q: Is Lomanor considered a high-risk medication during pregnancy?

A: Official labeling advises that Lomanor should only be used during pregnancy if the potential benefit justifies the potential risk to the fetus. The Australian TGA classification for this drug indicates that the drug should only be used if the benefit is considered necessary.

Q: What information is available about Lomanor use during breastfeeding?

A: Regulatory warnings state that Amlodipine is excreted into human milk. The official recommendation is to discontinue breastfeeding or discontinue the drug. This decision should be determined by a healthcare provider, considering the drug's necessity for the mother.

Q: Is it true that Lomanor can cause changes in mood or sleep patterns?

A: Yes, official adverse reaction lists document insomnia (difficulty sleeping) as an uncommon side effect. Changes in mood, including anxiety and depression, are also noted as uncommon. Confusion is listed as a rare possible effect.

Q: Are people with diagnosed mental health conditions able to use Lomanor?

A: While there are no formal prohibitions against Lomanor use for people with mental health conditions, the official documentation of side effects includes insomnia, mood changes, and depression. Official information describes that caution may be a consideration for patients with certain pre-existing mental health conditions.

Q: Can Lomanor affect a person's ability to drive or operate machinery?

A: Official product information states that Lomanor can have a minor to moderate influence on a person’s ability to drive or use machinery. This is primarily due to potential side effects like dizziness, headache, fatigue, or nausea, which may be more pronounced when treatment is initiated.

Q: Do studies suggest Lomanor works better for certain patient groups?

A: Research evidence describes that the medication was studied in diverse groups, including older adults and children (aged 6 and older for hypertension). Some studies have reported different observed patterns in specific populations or when compared to other drug regimens.

Q: Can Lomanor cause vision changes?

A: Yes, official regulatory documents list visual disturbance as an uncommon side effect. This includes the documentation of double vision (diplopia) among the adverse reactions reported in clinical use.

Q: How are the side effects of Lomanor managed generally?

A: The official information notes that the incidence of certain side effects, such as peripheral edema (swelling in the hands or feet), is described as dose-dependent. This finding may be used by healthcare professionals as a factor when considering dose adjustments to help manage these effects.

Q: Is there a generic version of Lomanor available?

A: Yes, the active ingredient, Amlodipine besylate, is widely available as a generic drug. This occurred after the original patents for the medication expired, making the generic form available as an alternative to the branded product.

Q: Are there any specific lab tests required before or during Lomanor treatment?

A: Routine laboratory monitoring is generally not required for all patients taking Lomanor. However, specific monitoring of blood levels is needed, along with potential dose adjustments, when Lomanor is used alongside certain interacting drugs like Tacrolimus and Cyclosporine.

Q: Is Lomanor available in all countries, or is it restricted geographically?

A: The drug is authorized via national regulatory procedures across major regions, including the European Union (EU), United States, and Canada. This regulatory status suggests widespread international availability, although it may be sold under various brand names.

Q: Does taking Lomanor at a specific time of day matter?

A: The official instruction is to take the medication once daily and that it should be taken at the same time each day to ensure consistent drug levels in the blood. There is no specific requirement for morning versus evening dosing, but consistency is a key factor.

How to Store and Dispose of Lomanor (Amlodipine)

Lomanor (amlodipine) must be stored according to specific regulatory requirements to maintain its stability.

Official Storage Conditions

Requirement	Official Statement
Temperature	Store at Controlled Room Temperature, 20 C to 25 C (68 F to 77 F).
Protection	Protect from light and moisture.
Container	Keep in the original container, which should be tight and light-resistant.
Child Safety	Keep out of reach of children.

Disposal

Disposal of unused or expired Lomanor must be handled in accordance with local requirements. Regulatory guidance recommends utilizing authorized drug take-back programs. If a program is unavailable, non-flushable medicines should be mixed with an undesirable substance before being placed in household trash.